This company has been marked as potentially delisted and may not be actively trading. OncoCyte (OCX) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock OncoCyte (NASDAQ:OCX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.05%Number OfInsiders Buying(Last 12 Months)4Amount OfInsider Buying(Last 12 Months)$6.68MNumber OfInsiders Selling(Last 12 Months)0 Get OCX Insider Trade Alerts Want to know when executives and insiders are buying or selling OncoCyte stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCX Insider Buying and Selling by Quarter OncoCyte Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/7/2025Andrea S JamesCFOBuy97,561$2.05$200,000.05 2/7/2025Patrick W SmithMajor ShareholderBuy1,077,600$2.05$2,209,080.00 2/4/2025Patrick W SmithMajor ShareholderBuy25$2.02$50.50 1/31/2025Patrick W SmithMajor ShareholderBuy890$2.01$1,788.90 1/29/2025Patrick W SmithMajor ShareholderBuy3,880$2.01$7,798.80 1/13/2025Patrick W SmithMajor ShareholderBuy5,669$2.08$11,791.52 12/26/2024Andrew ArnoDirectorBuy12,500$2.11$26,375.00 12/26/2024Patrick W SmithMajor ShareholderBuy90,219$2.13$192,166.47 12/5/2024Andrea S JamesCFOBuy20,000$2.29$45,800.00 10/2/2024Andrea S JamesCFOBuy33,670$2.97$99,999.90 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/2/2024Broadwood Partners, L.P.Major ShareholderBuy1,315,339$2.95$3,880,250.05 (Data available from 1/1/2013 forward) OCX Insider Trading Activity - Frequently Asked Questions Who is on OncoCyte's Insider Roster? The list of insiders at OncoCyte includes Alfred D Kingsley, Andrea S James, Andrew Arno, Broadwood Partners, L.P., Josh Riggs, Patrick W Smith, and Pura Vida Investments, Llc. Learn more on insiders at OCX. What percentage of OncoCyte stock is owned by insiders? 2.05% of OncoCyte stock is owned by insiders. Learn more on OCX's insider holdings. Which OncoCyte insiders have been buying company stock? The following insiders have purchased OCX shares in the last 24 months: Andrea S James ($345,799.95), Andrew Arno ($126,374.10), Broadwood Partners, L.P. ($10,946,650.05), Josh Riggs ($10,000.50), and Patrick W Smith ($2,422,676.19). How much insider buying is happening at OncoCyte? Insiders have purchased a total of 5,114,641 OCX shares in the last 24 months for a total of $13,851,500.79 bought. OncoCyte Key ExecutivesMr. Joshua Riggs (Age 41)President, CEO & Director Compensation: $504.63kMr. James Liu (Age 28)Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer Compensation: $259.83kDr. Ekkehard Schutz M.D.Ph.D., Chief Science OfficerMr. Peter HongVP, General Counsel & SecretaryMr. Yuh-Min Chiang Ph.D.Senior Vice President of R&D and Product DevelopmentMs. Sandra O'DonaldSenior Vice President of Business OperationsDr. Michael D. West Ph.D. (Age 71)Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. More Insider Trading Tools from MarketBeat Related Companies IMRX Insider Transactions GALT Insider Transactions DSGN Insider Transactions DRUG Insider Transactions RCKT Insider Transactions TECX Insider Transactions CTMX Insider Transactions ABEO Insider Transactions CGC Insider Transactions LRMR Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Small Caps That Insiders Are Buying $100 Million Buyback in Upwork Stock Follows a Strong Quarter Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tCoreWeave and Madrigal's Insider Trades Flash Bullish SignalsPalantir Insider Selling: Risk Signal or Normal Activity? This page (NASDAQ:OCX) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoCyte Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share OncoCyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
